OncoMatch/Clinical Trials/NCT07263906
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
Is NCT07263906 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Anti-LILRA6 CAR-T cells for refractory acute myeloid leukemia.
Treatment: Anti-LILRA6 CAR-T cells — This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: LILRA6 overexpression (positive rate in bone marrow/tumor cells ≥ 20%)
The positive rate of LILRA6 expression in bone marrow/tumor cells is ≥ 20%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: targeted LILRA6 drug
Those who have received any other targeted LILRA6 drug treatment before.
Lab requirements
Blood counts
Absolute number of neutrophils ≥ 0.5×10^9 /L, Platelet count ≥ 30×10^9 /L, Hemoglobin ≥ 7.0 g/dl
Kidney function
Creatinine clearance rate (Cockcroft-Gault method) ≥ 45 mL/min
Liver function
Alanine aminotransferase and Aspartate aminotransferase ≤ 2.5× UNL; Serum total bilirubin ≤ 1.5× UNL
Cardiac function
Ejection fraction of the heart (EF) ≥ 45%; NYHA class III or IV excluded
Sufficient organ function reserve: Alanine aminotransferase and Aspartate aminotransferase ≤ 2.5× UNL (upper limit of normal value); Creatinine clearance rate (Cockcroft-Gault method) ≥ 45 mL/min; Serum total bilirubin ≤ 1.5× UNL; Ejection fraction of the heart (EF) ≥ 45%; In an indoor natural air environment, baseline oxygen saturation > 92%; Blood routine: All of the following criteria are met: Absolute number of neutrophils ≥ 0.5×10^9 /L, Platelet count ≥ 30×10^9 /L, Hemoglobin ≥ 7.0 g/dl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify